Navigation Links
Vasogen Announces Second Quarter 2009 Results
Date:7/14/2009

revenues and projected costs. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expects", "plans", "anticipates", "believes", "estimated", "predicts", "potential", "continue", "intends", "could", or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of these forward-looking statements. You should not place undue reliance on our forward-looking statements, which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the outcome of our strategic review, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factors, including the current status of our programs, on capital availability, the potential dilutive effects of any financing and other risks detailed from time to time in our public disclosure documents or other filings with the Canadian and U.S. securities commissions or other securities regulatory bodies. Additional risks and uncertainties relating to our Company and our business can be found in the "Risk Factors" section of our Annual Information Form and Form 20-F for the year ended November 30, 2008, as well as in our other public filings, including our Management's Discussion and Analysis for the period ended May 31, 2009. The forward-looking statements are made as of the date hereof, and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

                 Summary financial tables are provided below.


    VASOGEN INC.
    (A DEVELOPMENT STAGE COMPANY)
    Interim Consolidated Balance Sheets
    
'/>"/>
SOURCE Vasogen Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. Vasogen Provides Update on ACCLAIM II Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Jose, California (PRWEB) September 19, 2014 ... Nanotechnology and its potential to revolutionize the world ... agencies, multinational corporations and small start-ups. The early ... funded research projects largely due to the high ... investments. Government budgets earmarked for this evolving technology ...
(Date:9/19/2014)... , Sept. 19, 2014 Pfenex Inc. ... the development of high-value and difficult to manufacture proteins ... presenting at the 21 st Annual NewsMakers in ... . Bertrand Liang , chief executive officer ... development programs and business strategy on Friday, September 26, ...
(Date:9/19/2014)... -- Dublin ... the addition of the  "Micro Market Monitor : ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ,The ... segments in the chromatography market. The market was ... to reach $2.0 billion by 2019, at a ...
(Date:9/18/2014)... 18, 2014 HealthTronics, Inc ... interventional radiology products and services, announced that a ... and cryoablation) versus external beam radiotherapy (EBRT) is ... American Urological Association (MAAUA) Annual Meeting in Baltimore, ... Effectiveness of Cryosurgery and External Beam Radiation as ...
Breaking Biology Technology:Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Pfenex to Present at Upcoming Industry Conference on September 26 2Micro Market Monitor : Global Pre-packed Chromatography Columns 2HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2
... S.C., Dec. 1 Collexis Holdings, Inc.,(OTC ... semantic search and,knowledge discovery software, announced today ... association, to promote BiomedExperts.com,to the association,s 200+ ... as the primary professional network for,BioFlorida, helping ...
... company aided in the research of vein treatment methods led by Dr. ... develop a new medical device, which he will present this summer to ... ... 1, 2008-- A gift from a California company aided in the research ...
... Encorium Group, Inc.,(Nasdaq: ENCO ), a ... over 30 countries for many of the world,s leading,pharmaceutical ... it received a letter from Nasdaq stating that since ... period ended September 30, 2008 as of the,date of ...
Cached Biology Technology:BioFlorida Selects Collexis' BiomedExperts.com as the Primary Professional Network for its 200 Member Companies and Organizations 2BioFlorida Selects Collexis' BiomedExperts.com as the Primary Professional Network for its 200 Member Companies and Organizations 3BioFlorida Selects Collexis' BiomedExperts.com as the Primary Professional Network for its 200 Member Companies and Organizations 4Gift Aids Professor's Research into Vein Treatment 2Gift Aids Professor's Research into Vein Treatment 3Gift Aids Professor's Research into Vein Treatment 4Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing 2Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing 3
(Date:9/18/2014)... researchers have developed a unique method to use microbes ... rural areas. , The first microbe-powered, self-sustaining wastewater ... way to clean up waste from large farming operations ... , Professor Haluk Beyenal and graduate student Timothy Ewing ... the system in the online edition of Journal ...
(Date:9/18/2014)... into the Crimean-Congo hemorrhagic fever virus (CCHFV), a tick-borne ... similar to that caused by Ebolavirus, has identified new ... the potential to lead to novel targets for therapeutic ... reported in a paper published today in the journal ... the Texas Biomedical Research Institute and their colleagues, represents ...
(Date:9/18/2014)... times it,s demonstrated, it,s still hard to envision ... by using a signaling system called "quorum sensing," ... suit their population. In short, some bacteria "know" ... accordingly. , Once the population of quorum-sensing bacteria ... to pathogenic, or from unhelpful to helpful. The ...
Breaking Biology News(10 mins):Researchers develop unique waste cleanup for rural areas 2Research milestone in CCHF virus could help identify new treatments 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3
... a paper published in the October 2011 issue of ... researchers at Columbia University Medical Center led by Stephen ... photoreceptors in a mouse model for retinitis pigmentosa (RP) ... a heterogeneous disorder characterized by progressive degeneration of rod ...
... Calif., Sept. 30, 2011 A glucosamine-like dietary supplement ... according to a UC Irvine study. UCI,s Dr. ... N-acetylglucosamine (GlcNAc), which is similar to but more effective ... function of abnormal T-cells that in MS incorrectly direct ...
... Perez Olsen, Ph.D., a Weintraub Scholar in the Basic ... the recipient of the National Institutes of Health Director,s ... first group of 10 junior U.S. investigators to receive ... million to support their research over a five-year period; ...
Cached Biology News:Cell-specific mechanism-based gene therapy approach to treat retinitis pigmentosa 2Cell-specific mechanism-based gene therapy approach to treat retinitis pigmentosa 3Glucosamine-like supplement suppresses multiple sclerosis attacks 2Hutchinson Center scientist wins first NIH Director's Early Indpendence Award 2
... genome-wide microRNA expression profiling and built ... microfluidic on-chip synthesis platform. These microarrays ... comprehensive microRNA Expression Profiling Service. ... microRNA Microarray contains all known fish ...
... unique quantitative and qualitative capabilities of the ... LC/MS/MS Systems with the new Tempo nano ... a rapid solution for high sensitivity validation ... extensive sample preparation with high instrument selectivity ...
... of Agilent analytical solutions is the 6890N ... (LAN) allows you to share business and ... decision making. Just as its 6890 GC ... and performance needed for research and method ...
... The 6820 GC system combines world-class performance ... QA/QC software, Agilents world-renowned support and columns, ... and supplies--a combination that lets you reach ... based on dependable data. The Agilent 6820 ...
Biology Products: